MX394103B - Anticuerpos anti-angptl8 y usos de estos. - Google Patents

Anticuerpos anti-angptl8 y usos de estos.

Info

Publication number
MX394103B
MX394103B MX2018001532A MX2018001532A MX394103B MX 394103 B MX394103 B MX 394103B MX 2018001532 A MX2018001532 A MX 2018001532A MX 2018001532 A MX2018001532 A MX 2018001532A MX 394103 B MX394103 B MX 394103B
Authority
MX
Mexico
Prior art keywords
antibodies
angptl8
bind
angptl8 antibodies
certain embodiments
Prior art date
Application number
MX2018001532A
Other languages
English (en)
Other versions
MX2018001532A (es
Inventor
Andrew J Murphy
David R Buckler
Jesper Gromada
Viktoria Gusarova
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2018001532A publication Critical patent/MX2018001532A/es
Publication of MX394103B publication Critical patent/MX394103B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39575—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from other living beings excluding bacteria and viruses, e.g. protozoa, fungi, plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona anticuerpos que se unen a ANGPTL8 y métodos de uso de este. De acuerdo con ciertas modalidades, los anticuerpos de la invención se unen a ANGPTL8 humano con alta afinidad. Los anticuerpos de la invención pueden ser anticuerpos completamente humanos. Los anticuerpos de la invención son útiles para el tratamiento de varias enfermedades o trastornos caracterizados en parte por los niveles de triglicéridos en la sangre.
MX2018001532A 2015-08-07 2016-08-04 Anticuerpos anti-angptl8 y usos de estos. MX394103B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562202366P 2015-08-07 2015-08-07
PCT/US2016/045535 WO2017027316A1 (en) 2015-08-07 2016-08-04 Anti-angptl8 antibodies and uses thereof

Publications (2)

Publication Number Publication Date
MX2018001532A MX2018001532A (es) 2018-03-15
MX394103B true MX394103B (es) 2025-03-24

Family

ID=56979626

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018001532A MX394103B (es) 2015-08-07 2016-08-04 Anticuerpos anti-angptl8 y usos de estos.

Country Status (16)

Country Link
US (1) US10259870B2 (es)
EP (1) EP3331908B1 (es)
JP (2) JP7141333B2 (es)
KR (1) KR20180038020A (es)
CN (1) CN107922478A (es)
AR (1) AR105600A1 (es)
AU (1) AU2016307430B2 (es)
CA (1) CA2993976A1 (es)
EA (1) EA035088B1 (es)
ES (1) ES2870031T3 (es)
HK (1) HK1250238A1 (es)
IL (1) IL257263A (es)
MX (1) MX394103B (es)
TW (1) TW201713690A (es)
WO (1) WO2017027316A1 (es)
ZA (1) ZA201800352B (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
US10071139B2 (en) * 2014-10-03 2018-09-11 Ngm Biopharmaceuticals, Inc. Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
ES2951262T3 (es) * 2016-02-17 2023-10-19 Regeneron Pharma Métodos para tratar o prevenir la aterosclerosis mediante la administración de un inhibidor de ANGPTL3
KR102456731B1 (ko) 2016-03-03 2022-10-24 리제너론 파아마슈티컬스, 인크. Pcsk9 억제제를 angptl3 억제제와 병용하여 투여함으로써 고지혈증을 갖는 환자를 치료하기 위한 방법
US11542332B2 (en) 2016-03-26 2023-01-03 Bioatla, Inc. Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
LT3439689T (lt) * 2016-04-08 2021-11-10 Regeneron Pharmaceuticals, Inc. Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
EA201991203A1 (ru) * 2016-11-17 2019-10-31 Способы лечения ожирения антителами к angptl8
JP6853716B2 (ja) * 2017-03-31 2021-03-31 信越化学工業株式会社 レジスト下層膜材料、パターン形成方法、及びレジスト下層膜形成方法
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2019006162A1 (en) 2017-06-28 2019-01-03 Bluefin Biomedicine, Inc. ANTI-LY6H ANTIBODIES AND CONJUGATES ANTIBODY-MEDICINE
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
SG11202003980PA (en) 2017-10-31 2020-05-28 Staten Biotechnology B V Anti-apoc3 antibodies and methods of use thereof
CA3080148A1 (en) 2017-11-10 2019-05-16 Ngm Biopharmaceuticals, Inc. Angptl8-binding agents and methods of use thereof
WO2019126194A1 (en) * 2017-12-18 2019-06-27 Regeneron Pharmaceuticals, Inc. Angptl8 assay and uses thereof
WO2019173438A1 (en) * 2018-03-06 2019-09-12 Stc. Unm Compositions and methods for reducing serum triglycerides
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
JP2022521551A (ja) 2019-02-26 2022-04-08 ツイスト バイオサイエンス コーポレーション Ｇｌｐ１受容体の変異体核酸ライブラリ
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
JP2022540806A (ja) 2019-07-19 2022-09-20 オンコレスポンス，インク． 免疫調節抗体およびその使用方法
CN110613847B (zh) * 2019-10-23 2022-02-11 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
CN110694068A (zh) * 2019-11-06 2020-01-17 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
CN110694067A (zh) * 2019-11-06 2020-01-17 首都医科大学附属北京安贞医院 一种抑制血管生成素样蛋白8的物质的应用
CN111135303A (zh) * 2020-01-17 2020-05-12 北京市心肺血管疾病研究所 一种抑制血管生成素样蛋白8的物质的应用
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CA3190667A1 (en) 2020-08-26 2022-03-03 Aaron Sato Methods and compositions relating to glp1r variants
WO2023213779A1 (en) * 2022-05-02 2023-11-09 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
WO2024069614A1 (en) * 2022-09-30 2024-04-04 9163-0384 Québec Inc Methods for the assessment of lipoprotein lipase deficiency and lipoprotein lipase bioavailability
CN119192369A (zh) * 2023-06-25 2024-12-27 百奥泰生物制药股份有限公司 抗angptl3抗体及其应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
WO1999040100A1 (en) 1998-02-09 1999-08-12 Human Genome Sciences, Inc. 45 human secreted proteins
US6930170B2 (en) 1997-06-16 2005-08-16 Genentech, Inc. PRO1184 polypeptides
US7393663B2 (en) 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
NZ523206A (en) 1999-08-31 2004-12-24 Genentech Inc Antibodies that bind to tumor gene sequences
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US7537903B2 (en) 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
CA2687746A1 (en) 2007-05-22 2008-12-18 Novartis Ag Methods of treating, diagnosing and detecting fgf21-associated disorders
MX2012006397A (es) * 2009-12-02 2012-11-30 Amgen Inc PROTEINAS DE ENLACE QUE ENLAZAN A FGFR1C HUMANO, ß-KLOTHO HUMANA Y TANTO FGFR1C HUMANO COMO ß-KLOTHO HUMANA.
JO3274B1 (ar) 2009-12-24 2018-09-16 Regeneron Pharma أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري
US20120021409A1 (en) * 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
AU2012267492A1 (en) * 2011-06-10 2014-01-09 President And Fellows Of Harvard College Modulation of pancreatic beta cell proliferation
JO3412B1 (ar) 2011-06-17 2019-10-20 Regeneron Pharma أجسام مضادة ل angptl3 واستخداماتها
WO2013106547A1 (en) * 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
US20140178988A1 (en) * 2012-10-08 2014-06-26 Biotime, Inc. Differentiated Progeny of Clonal Progenitor Cell Lines
WO2014183207A1 (en) * 2013-05-17 2014-11-20 Exerkine Corporation Therapeutic method of treating metabolic syndrome
CN104164451A (zh) * 2014-08-09 2014-11-26 高连如 一种治疗2型糖尿病的基因工程干细胞
US10071139B2 (en) * 2014-10-03 2018-09-11 Ngm Biopharmaceuticals, Inc. Methods for treatment of conditions associated with elevated triglycerides with an ANGPTL8 polypeptide fragment
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
LT3439689T (lt) 2016-04-08 2021-11-10 Regeneron Pharmaceuticals, Inc. Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi
EA201991203A1 (ru) 2016-11-17 2019-10-31 Способы лечения ожирения антителами к angptl8

Also Published As

Publication number Publication date
EP3331908B1 (en) 2021-03-10
MX2018001532A (es) 2018-03-15
CA2993976A1 (en) 2017-02-16
JP2021090449A (ja) 2021-06-17
US10259870B2 (en) 2019-04-16
KR20180038020A (ko) 2018-04-13
US20170037124A1 (en) 2017-02-09
WO2017027316A1 (en) 2017-02-16
EA201890453A1 (ru) 2018-07-31
AR105600A1 (es) 2017-10-18
AU2016307430B2 (en) 2022-04-21
EP3331908A1 (en) 2018-06-13
TW201713690A (zh) 2017-04-16
HK1250238A1 (zh) 2018-12-07
AU2016307430A1 (en) 2018-02-22
ES2870031T3 (es) 2021-10-26
JP2018525383A (ja) 2018-09-06
CN107922478A (zh) 2018-04-17
ZA201800352B (en) 2018-12-19
EA035088B1 (ru) 2020-04-27
IL257263A (en) 2018-03-29
JP7141333B2 (ja) 2022-09-22

Similar Documents

Publication Publication Date Title
MX394103B (es) Anticuerpos anti-angptl8 y usos de estos.
EA201790377A1 (ru) Антитела к глюкагону и их применения
MX377712B (es) Anticuerpos dirigidos contra il-33 y sus usos.
SA519401522B1 (ar) Lag-3 أجـسـام مـضـادة لـ وتـركـيـبـات
JOP20190093A1 (ar) أجسام مضادة لـ il-33 واستخداماتها
MX2024010175A (es) Moleculas de anticuerpo contra april y usos de las mismas.
EA202090031A3 (ru) Человеческие антитела против gfr3 и способы их применения
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
PH12015501493A1 (en) Anti-pdgfr-beta antibodies and uses thereof
MX385845B (es) Usos y composiciones de la flagelina
UY35682A (es) Anticuerpos anti-activina a y usos de los mismos
EA201692109A1 (ru) Варианты антител к фактору d и их применение
EA201992707A1 (ru) Соединения и их применения для модуляции гемоглобина
EA201501061A1 (ru) Антитела к igf-1r с элиминированной способностью связываться с fcrn и их применение для лечения сосудистых глазных заболеваний
EA201891594A1 (ru) Антитела к il-17c
EA201491522A1 (ru) Способы лечения нарушения походки и/или равновесия у пациентов с рассеянным склерозом с использованием аминопиридина
EA201501176A1 (ru) Замещенные бензоксазолы
HK1235409A1 (en) Anti-glucagon antibodies and uses thereof